Comparative analysis of the use and control of thalidomide in Brazil and different countries: is it possible to say there is safety?

References

• Lary JM, Daniel KL, Erickson JD, et al. The return of thalidomide: can birth defects be prevented? Drug Saf. 1999;21(3):161–169. .
   PubMed Web of Science ®Google Scholar
• Oliveira MA, Bermudez JAZ, Souza ACM. Talidomida no Brasil: vigilância com responsabilidade compartilhada? [Thalidomide in Brazil: monitoring with share responsability?]. Cad Saúde Pública. 1999;15(1):99–112. Portuguese. .
   PubMedGoogle Scholar
• Papaseit E, García-Algar O, Farré M. Thalidomide: an unfinished history. An Pediatr (Barc). 2013;78(5):283–287.
   PubMed Web of Science ®Google Scholar
• Vargesson N. Thalidomide‐induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today. 2015;105(2):140–156.
   PubMedGoogle Scholar
• Moro A. Participação Social e Regulação de Medicamentos: o Caso da Talidomida no Brasil. [Social Participation and Drug Regulation: the Case of Thalidomide in Brazil] [dissertation]. Curitiba (PR): Federal University of Paraná. 2017. Portuguese.
   Google Scholar
• Moro A, Invernizzi N. A tragédia da talidomida: a luta pelos direitos das vítimas e por melhor regulação de medicamentos. [The thalidomide tragedy: the struggle for victims’ right and improved pharmaceutical regulation]. Hist. cienc. saúde-Manguinhos, 2017;24(3):603–622. Portuguese. ;():. .
   PubMedGoogle Scholar
• Santos FLA História da Talidomida no Brasil e a trajetória para conquista de direitos das pessoas com a Síndrome Teratogênica. [The History of Thalidomide in Brazil and the path to achieving the rights of people with the Teratogenic Syndrome] [dissertation]. Ponta Grossa (SP): State University of Ponta Grossa. 2018. Portuguese.
   Google Scholar
• Gollop TR, Eigier A, Guidugli Neto J. Prenatal diagnosis of thalidomide syndrome. Prenat Diagn. 1987;7(4):295–298.
   PubMed Web of Science ®Google Scholar
• Castilla EE, Ashton-Prolla P, Barreda-Mejia E, et al. Thalidomide, a Current Teratogen in South America. Teratology. 1996;54(6):273–277.
   PubMedGoogle Scholar
• Vianna FSL, Lopez-Camelo JS, Leite JC, et al., Epidemiological Surveillance of Birth Defects Compatible with Thalidomide Embryopathy in Brazil. PLoSOne. 6(7): e21735. 2011. .
   PubMed Web of Science ®Google Scholar
• Vianna FSL, Schuler-Faccini L, Leite JC, et al. Recognition of the phenotype of thalidomide embryopathy in countries endemic for leprosy: new cases and review of the main dysmorphological findings. Clin Dysmorphol. 2013;22(2):59–63. .
   PubMed Web of Science ®Google Scholar
• Vianna FSL, Oliveira MZ, Sanseverino MT, et al. Pharmacoepidemiology and thalidomide embryopathy surveillance in Brazil. Reprod Toxicol. 2015;53:63–67.
   PubMed Web of Science ®Google Scholar
• Vargesson N. The teratogenic effects of thalidomide on limbs. J Hand Surg Eur Vol. 2019;44(1):88–95.*. .
   Web of Science ®Google Scholar
• Edmonds LD. Congenital Malformations Surveillance: two American Systems. Int J Epidemiol. 1981;10(3):247–252.
   PubMed Web of Science ®Google Scholar
• Hans M, Gupta SK. Comparative evaluation of pharmacovigilance regulation of the United States, United Kingdom, Canada, India and the need for global harmonized practices. Perspect Clin Res. 2018;9(4):170–174.
   PubMedGoogle Scholar
• Khalil A, Kamar A, Nemer G. Thalidomide-Revisited: are COVID-19 Patients Going to Be the Latest Victims of Yet Another Theoretical Drug-Repurposing? Front Immunol. 2020;11:1248.
   PubMed Web of Science ®Google Scholar
• SMd J, Santana RS, Leite SN. The organization, weaknesses, and challenges of the control of thalidomide in Brazil: a review. PLoS Negl Trop Dis. 2020;14(8):e0008329. .
   PubMed Web of Science ®Google Scholar
• Saúde SDVE. Gestantes em uso de talidomida no Brasil: novos casos relatados após a publicação da RDC ANVISA nº 11/2011 [Pregnant women using thalidomide in Brazil: new cases reported after the publication of RDC ANVISA no. 11/2011]. 2021;52(14):15–23. Boletim Epidemiológico.
   Google Scholar
• Sheskin J. Thalidomide in the treatment of lepra reaction. Clin Pharmacol Ther. 1965;6(3):303–306.
   PubMed Web of Science ®Google Scholar
• Jones GR. Thalidomide: 35 years on and still deforming. Lancet. 1994;343(8904):1041.
   PubMed Web of Science ®Google Scholar
• Cutler J. Thalidomide revisited. Lancet. 1994;343(8900):795–796.
   PubMed Web of Science ®Google Scholar
• Yang Q, Khoury MJ, James LM, et al. The Return of Thalidomide: are Birth Defects Surveillance Systems Ready? Am J Med Genet. 1997;73(3):251–258. .
   PubMed Web of Science ®Google Scholar
• Irl C, Kipferler P, Hasford J. Drug Use Assessment and Risk Evaluation in Pregnancy - The PEGASUS-Project. Pharmacoepidemiol Drug Saf. 1997;6(3):37–42.
   PubMedGoogle Scholar
• Zeldis JB, Williams BA, Thomas SD, et al. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther. 1999;21(2):319–330. .
   PubMed Web of Science ®Google Scholar
• Timmermans S, Leiter V. The Redemption of Thalidomide: standardizing the Risk of Birth Defects. Soc Stud Sci. 2000;30(1):41–71.
   PubMed Web of Science ®Google Scholar
• Andrews E, Dombeck M. The role of scientific evidence of risks and benefits in determining risk management policies for medications. Pharmacoepidemiol Drug Saf. 2004;13(9):599–608.
   PubMed Web of Science ®Google Scholar
• Uhl K, Cox E, Rogan R, et al. Thalidomide use in the US: experience with pregnancy testing in the. S.T.E.P.S. programme. Drug Saf. 2006;29(4):321–329.
   PubMed Web of Science ®Google Scholar
• Shanbhag PS, Viswanath V, Torsekar RG. Thalidomide: current status. Indian J Dermatol Venereol Leprol. 2006;72(1):75–80.
   PubMedGoogle Scholar
• Johnson M. Integrating health information: a case study of a health information service for thalidomide survivors. Med Inform Internet Med. 2007;32(1):27–33.
   PubMed Web of Science ®Google Scholar
• Schuler-Faccini L, Soares RC, de Sousa AC, et al. New Cases of Thalidomide Embryopathy in Brazil. Birth Defects Res A Clin Mol Teratol. 2007;79(9):671–672. .
   PubMedGoogle Scholar
• Ooba N, Sato T, Watanabe H, et al. Resolving a Double Standard for Risk Management of Thalidomide: an Evaluation of Two Different Risk Management Programmes in Japan. Drug Saf. 2010;33(1):35–45. .
   PubMed Web of Science ®Google Scholar
• Minuk L, Sibbald R, Peng J, et al. Access to thalidomide for the treatment of multiple myeloma in Canada: physician behaviours and ethical implications. Cuur Oncol. 2010;17(4):11–19.
   PubMed Web of Science ®Google Scholar
• Bwire R, Freeman J, Houn F. Managing the teratogenic risk of thalidomide and lenalidomide: an industry perspective. Expert Opin Drug Saf. 2011;10(1):3–8.
   PubMed Web of Science ®Google Scholar
• Paim J, Travassos C, Almeida C, et al. The Brazilian health system: history, advances, and challenges. Lancet. 2011;377(9779):1778–1797. .
   PubMed Web of Science ®Google Scholar
• Crijns I, Zomerdijk I, Sturkenboom M, et al., A comparison of pregnancy prevention programmes in Europe. Expert Opin Drug Saf. 13(4): 411–420. 2014. .
   PubMed Web of Science ®Google Scholar
• Freeman J, Bwire R, Haoun F, et al. Teratogenic Drugs and Risk Management: an Implementation Assessment. Ther Innov Regul Sci. 2014;48(4):420–427. .
   PubMed Web of Science ®Google Scholar
• Brandenburg NA, Bwire R, Freeman J, et al. Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: patient Comprehension and Knowledge Retention. Drug Saf. England. 2017;40(4):333–341.
   PubMed Web of Science ®Google Scholar
• Baba S, Tsujita S, Marimoto K. The Analysis of Trends in Induced Abortion in Japan – an Increasing Consequence among Adolescents. Environ Health Prev Med. 2005;10(1):9–15.
   PubMedGoogle Scholar
• Penchaszadesh VB. Preventing Congenital Anomalies in Developing Countries. Community Genet. 2002;5(1):61–69.
   PubMedGoogle Scholar
• Penna GO, Martelli CMT, Stefani MMA, et al. Thalidomide in the treatment of erythema nodosum leprosum (ENL): systematic review of clinical trials and prospects of new investigations; An. Bras. Dermatol. 2005;80(5):511–522.
   Google Scholar
• Iyer CG, Languillon J, Tarabini-Castellani G, et al. WHO co-ordinated short-term double-blind trial with thalidomide in thetreatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ. 1971;45(6):719–732.
   PubMed Web of Science ®Google Scholar
• Clark TE, Edom N, Larson J, et al. Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous post marketing adverse event surveillance, including off-label prescribing. Drug Saf. 2011;24(2):87–117. .
   Google Scholar
• Daemmerich A. A tale of two experts: thalidomide and political engagement in the United States and West Germany. Soc Hist Med. 2002;15(1):137–158.
   PubMed Web of Science ®Google Scholar
• Lachmann PJ. The penumbra of thalidomide, the litigation culture and the licensing of pharmaceutical. QJM. 2012;105(12):1179–1189.
   PubMed Web of Science ®Google Scholar
• Olivier-Abbal P, Teisseyre AC, Montastruc JL, et al. Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database. Med Oncol. 2013;30(4):733. .
   PubMed Web of Science ®Google Scholar
• Biswas P. Pharmacovigilance in Asia. J Pharmacol Pharmacother. 2013;4(suppl1):S7–S19.
   PubMedGoogle Scholar
• Upputuri B, Pallapati MS, Tarwater P, et al. Thalidomide in the treatment of erythema nodosum leprosum (ENL) in an outpatient setting: a five-year retrospective analysis from a leprosy referral centre in India. PLoS Negl Trop Dis. 2020;14(10):e0008678. .
   PubMed Web of Science ®Google Scholar
• Rao PN, Rathod S, Sujai S, et al. The Dermlep Stydy Part 2: results pf a Nation-Wide Survey of Dermatologists’ Access to Quality Leprosy Services at their Clinics and Hospitals in India. Indian Dermatol Online J. 2020;11(6):895–903.
   PubMedGoogle Scholar
• Chisholm C. The Curious Case of Thalidomide and the Absent Eugenic Clause in Canada’s Amended Abortion Law of 1969. Can Bull Med Hist. 2016;33(2):493–516.
   PubMed Web of Science ®Google Scholar
• Costa PDSS, Fraga LR, Kowalski TW, et al. Erythema Nodosum Leprosum: update and challenges on the treatment of a neglected condition. Acta Trop. 2018;183:134–141.
   PubMed Web of Science ®Google Scholar
• Vianna FSL Talidomida no Brasil: vigilância Epidemiológica, Teratogênese e Farmacogenética. [Thalidomide in Brazil: epidemiological Surveillance, Teratogenesis and Pharmacogenetics] [dissertation]. Porto Alegre (RS): Federal University of Rio Grande do Sul. 2013. Portuguese.
   Google Scholar
• Lei nº 7.070, de 20 de dezembro de 1982. Dispõe sobre pensão especial para os deficientes físicos que especifica e dá outras providencias [Law No. 7070, of December 20, 1982. Provides for special pension for the physically deficient that it specifies and makes other provisions]. Brasília (DF): Presidência da República; 1982 Dec 21 [cited 2019 Oct 14]. Portuguese.
   Google Scholar
• Portaria nº 354, de 15 de agosto de 1997. Regulamentar o registro, a produção, a fabricação, a comercialização, a exposição à venda, a prescrição e a dispensação dos produtos à base de talidomida [Ordinance No. 354, of August 15, 1997. Regulates the registration, production, manufacturing, commercialization, sale, prescription, and dispensation of thalidomide-based products.]. Brasília (DF): Ministério da Saúde; 1997 Aug 18 [cited 2019 Oct 14]. Portuguese.
   Google Scholar
• Lei nº 9.782, de 26 de janeiro de 1999. Define o Sistema Nacional de Vigilância Sanitária, cria a Agência Nacional de Vigilância Sanitária, e dá outras providências [Law No. 9782, of January 26, 1999. Defines the National Sanitary Surveillance System, creates the National Health Surveillance Agency, and makes other provisions]. Brasília (DF): Presidência da República; 1999 Jan 27 [cited 2019 Oct 14]. Portuguese.
   Google Scholar
• Resolução da Diretoria Colegiada nº 34, de 20 de abril de 2000. Dispõe sobre a utilização da Talidomida no tratamento da mieloma múltiplo refratário a quimioterapia [Collegiate Board Resolution No. 34, of April 20, 2000. Provides on the use of Thalidomide in the treatment of multiple myeloma refractory to chemotherapy]. Brasília (DF): Agência Nacional de Vigilância Sanitária; 2000 Apr 20 [cited 2019 Oct 14]. Portuguese.
   Google Scholar
• Lei nº 10.651, de 16 de abril de 2003. Dispõe sobre o controle do uso da talidomida [Law No. 10651, of April 16, 2003. Provides on the control of the use of thalidomide]. Brasília (DF): presidência da República; 2003 Apr 17 [ cited 2019 Oct 14]. Portuguese.
   Google Scholar
• Lei nº 12.190, de 13 de janeiro de 2010. Concede indenização por dano moral às pessoas com deficiência física decorrente do uso da talidomida, altera a Lei no 7.070, de 20 de dezembro de 1982, e dá outras providências [Law No. 12190, of January 13, 2010. Grants compensation for moral damage to people with physical disabilities resulting from the use of thalidomide, amends Law 7070 of December 20, 1982, among other provisions]. Brasília (DF): presidência da República; 2010 Jan 13 [cited 2019 Oct 14]. Portuguese.
   Google Scholar
• Resolução da Diretoria Colegiada nº 11, de 22 de março de 2011. Dispõe o controle da substância Talidomida e do medicamento que a contenha [Collegiate Board Resolution No. 11, of March 22, 2011. Provides for the control of the substance Thalidomide and the drug containing it]. Brasília (DF): agência Nacional de Vigilância Sanitária; 2011 Mar 22 [cited 2019 Oct 14]. Portuguese.
   Google Scholar
• Portaria nº 298 de 21 de março de 2013. Atualiza os protocolos de uso da Talidomida no tratamento da Doença Enxerto Contra Hospedeiro e do Mieloma Múltiplo [Ordinance No. 298 of March 21, 2013. Updates the protocols for the use of Thalidomide in the treatment of Graft-versus-Host Disease and Multiple Myeloma]. Brasília (DF): ministério da Saúde; 2013 Mar 22 [cited 2019 Oct 14]. Portuguese.
   Google Scholar
• Portaria nº 100, de 7 de fevereiro de 2013. Aprova o Protocolo Clínico e Diretrizes Terapêuticas do Lúpus Eritematoso Sistêmico [Ordinance No. 100, of February 7, 2013. Approves the Clinical Protocol and Therapeutic Guidelines for Systemic Lupus Erythematosus]. Brasília (DF): ministério da Saúde; 2013 Feb 02 [cited 2019 Oct 14]. Portuguese.
   Google Scholar
• Portaria nº 45 de 16 de dezembro de 2014. Torna pública a decisão de ampliar o uso da talidomida para tratamento da síndrome mielodisplásica no âmbito do Sistema Único de Saúde – SUS [rdinance No. 45 of December 16, 2014. Makes public the decision to expand the use of thalidomide for the treatment of myelodysplastic syndrome within the Unified Health System - SUS]. Brasília (DF): ministério da Saúde; 2014 Dec 17 [cited 2019 Oct 14]. Portuguese.
   Google Scholar
• Resolução da Diretoria Colegiada nº 50, de 11 de novembro de 2015. Dispõe sobre a atualização do Anexo III, Indicações previstas para tratamento com a Talidomida, da RDC nº 11, de 22 de março de 2011 [Collegiate Board Resolution No. 50, of November 11, 2015. Provides for the update of Annex III, Indications for treatment with Thalidomide, from RDC No. 11, dated March 22, 2011]. Brasília (DF): ministério da Saúde; 2015 Nov 12 [cited 2019 Oct 14]. Portuguese.
   Google Scholar
• Portaria nº 493, de 11 de junho de 2015. Aprova o Protocolo de uso da talidomida no tratamento da síndrome mielodisplásica [Ordinance No. 493, of June 11, 2015. Approves the Protocol for the use of thalidomide in the treatment of myelodysplastic syndrome]. Brasília (DF): ministério da Saúde; 2015 Jun 12 [cited 2019 Oct 14]. Portuguese.
   Google Scholar
• Portaria nº 2.436, de 21 de setembro de 2017. Aprova a Política Nacional de Atenção Básica, estabelecendo a revisão de diretrizes para a organização da Atenção Básica, no âmbito do Sistema Único de Saúde (SUS) [Ordinance No. 2436, of September 21, 2017. Approves the National Policy for Primary Care, establishing the revision of guidelines for the organization of Primary Care, within the Unified Health System (SUS)]. Brasília (DF): ministério da Saúde; 2017 Sep 22 [cited 2019 Oct 14]. Portuguese.
   Google Scholar
• Lei nº 13.638, de 22 de março de 2018. Altera a Lei nº 8.686, de 20 de julho de 1993, para estabelecer novo valor para a pensão especial devida à pessoa com a deficiência física conhecida como Síndrome da Talidomida, instituída pela Lei nº 7.070, de 20 de dezembro de 1982 [Law No. 13638, of March 22, 2018. Amends Law No. 8686, of July 20, 1993, to establish new value for the special pension due to the person with the physical disability known as Thalidomide Syndrome, instituted by Law No. 7070, of December 20, 1982]. Brasília (DF): presidência da República; 2018 Mar 23 [cited 2019 Oct 14]. Portuguese.
   Google Scholar
• FUNED - Talidomida [FUNED - Thalidomide]. [Internet]. Brasília (DF): agência Nacional de Vigilância Sanitária. Consultas Medicamentos; [ cited 2019 Oct 14]. Available from: https://consultas.anvisa.gov.br/#/medicamentos/. Portuguese.
   Google Scholar
• Talidomida [Thalidomide]. [Internet]. Belo Horizonte (MG): fundação Ezequiel Dias; [ cited 2019 Oct 14]. Available from: http://www.funed.mg.gov.br/talidomida/. Portuguese.
   Google Scholar
• Farmacovigilância [Pharmacovigilance]. [Internet]. Brasília (DF): agência Nacional de Vigilância Sanitária; [ cited 2019 Oct 14]. Available from: http://portal.anvisa.gov.br/farmacovigilancia?inheritRedirect=true. Portuguese.
   Google Scholar
• Talidomida: orientação para paciente [Thalidomide: patient Guide]. Brasília (DF): ministério da Saúde; [ cited 2019 Oct 14]. Available from: https://portalarquivos2.saude.gov.br/images/pdf/2016/novembro/14/2016-0393-Folder-Talidomida.pdf. Portuguese.
   Google Scholar
• Sistema de Informação sobre Mortalidade [Mortality Information System]. [Internet]. Brasília (DF): ministério da Saúde. Departamento de Análises de Saúde e Vigilância de Doenças Não Transmissíveis; [ cited 2019 Oct 14]. Available from: http://svs.aids.gov.br/dantps/cgiae/sim/apresentacao/. Portuguese.
   Google Scholar
• Estudo Colaborativo Latino-Americano de Malformações Congênitas [Latin American Collaborative Study of Congenital Malformations]. [Internet]. Rio de Janeiro/Buenos Aires (RJ/BA): ECLAMC, [ cited 2019 Oct 14]. Available from: http://www.eclamc.org/port/index.php. Portuguese.
   Google Scholar
• Sistema de Informações de Nascidos Vivos [Live Births Information System]. [Internet]. Brasília (DF): ministério da Saúde; [ cited 2019 Oct 14]. Available from: http://datasus.saude.gov.br/sistemas-e-aplicativos/eventos-v/sinasc-sistema-de-informacoes-de-nascidos-vivos. Portuguese.
   Google Scholar
• Secretaria de Vigilância em Saúde. Talidomida: orientação para o uso controlado. [Thalidomide: guidance for controlled use]. Brasília (DF): ministério da Saúde; 2014. Portuguese.
   Google Scholar
• Associação Brasileira das Vítimas da Talidomida [Brazilian Thalidomide Victims Association]. [Internet]. Belo Horizonte (MG): ABVT; [ cited 2019 Oct 14]. Available from: https://abvt.wordpress.com/. Portuguese.
   Google Scholar
• Associação Brasileira de Portadores de Síndrome de Talidomida [Brazilian Association of Thalidomide Syndrome’s Victims]. [Internet]. São Paulo (SP): ABPST; [ cited 2019 Oct 14]. Available from: http://www.talidomida.org.br/. Portuguese.
   Google Scholar
• Decreto-Lei nº 2.848, de 07 de dezembro de 1940. Código Penal [Decree-Law No. 2848, of December 7, 1940. Penal Code]. Brasília (DF): presidência da República; 1940 Dec 31 [cited 2019 Oct 14]. Portuguese.
   Google Scholar
• What does FDA regulate? [Internet]. Washington (DC): food and Drug Administration. About FDA; [ cited 2019 Oct 14]. Available from: https://www.fda.gov/about-fda/fda-basics/what-does-fda-regulate.
   Google Scholar
• Laws Enforced by FDA. [Internet]. Washington (DC): food and Drug Administration. Regulatory Information; 2018 Mar 29 [cited 2019 Oct 14]. Available from: https://www.fda.gov/regulatory-information/laws-enforced-fda.
   Google Scholar
• Drugs FD-A-A. [Internet]. Washington (DC): Food and Drug Administration. Drug Databases; 1998 Jul 16 [cited 2019 Oct 14]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020785.
   Google Scholar
• Prescription Drug Labeling Resources. [Internet]. Washington (DC): food and Drug Administration. Laws, Acts, and Rules; 2019 Jul 01 [cited 2019 Oct 14]. Available from: https://www.fda.gov/drugs/laws-acts-and-rules/prescription-drug-labeling-resources.
   Google Scholar
• Risk Evaluation and Mitigation Strategies│REMS. [Internet]. Washington (DC): Food and Drug Administration. Drug Safety and Availability; 2019 Aug 08 [cited 2019 Oct 14]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems.
   Google Scholar
• Metropolitan Atlanta Congenital Defects Program (MACDP). [Internet]. Atlanta (GA): centers for Disease Control and Prevention. Research & Tracking; 2018 Dec 07 [cited 2019 Oct 14]. Available from: https://www.cdc.gov/ncbddd/birthdefects/macdp.html.
   Google Scholar
• Birth Defects Monitoring Program (BDMP). [Internet]. Atlanta (GA): centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report; 1983 Feb 01 [cited 2019 Oct 14]. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/00014666.htm.
   Google Scholar
• Thalidomide Survivors in the US. [Internet]. Minneapolis (MN): US Thalidomide Survivors, [ cited 2019 Oct 14]. Available from: https://usthalidomide.org.
   Google Scholar
• U.S. Reports: Roe v. Wade, 410 U.S. 113 (1973). [Internet]. Washington (DC): Library of Congress. Legislation; [ cited 2019 Oct 14]. Available from: https://www.loc.gov/item/usrep410113/.
   Google Scholar
• U.S. Reports: Planned Parenthood of Southeastern Pennsylvania v. Casey, 505 U.S. 833 (1992). [Internet]. Washington (DC): Library of Congress. Legislation; [ cited 2019 Oct 14]. Available from: https://www.loc.gov/item/usrep505833/.
   Google Scholar
• Pharmaceuticals and Medical Devices Agency. [Internet]. Chiyoda-ku (TYO): PMDA, [ cited 2019 Oct 14]. Available from: https://www.pmda.go.jp/english/index.html.
   Google Scholar
• Drug Safety Research Unit Japan. Information for the operation of Safety Management system for Unapproved Drugs (SMUD). [Internet]. Chiyoda-ku (TYO): ministry of Health, Labour and Welfare of Japan, [ cited 2019 Oct 14]. Available from: http://www.dsrujp.org/smudinfo/smudinformation_e.html.
   Google Scholar
• Ishii N, Ishida Y, Okano Y, et al. Guideline for clinical use of thalidomide for management of erythema nodosum leprosum in Japan. [Internet]. Japanese Journal of Leprosy. 2017;86(2):91–100. Available from: https://doi.org/https://doi.org/10.5025/hansen.86.91.
   Google Scholar
• Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices. [Internet]. Chiyoda-ku (TYO): ministry of Justice. Japanese Law Translation Database System; 2015 Mar 31 [cited 2019 Oct 14]. Available from: http://www.japaneselawtranslation.go.jp/law/list/?ft=1&re=2&dn=1&ky=pharmaceutical+affairs&x=52&y=17&co=01í03.
   Google Scholar
• Japan Society Obstetrics and Gynecology. [Internet]. Chuo-ku (TYO): JAOG, [ cited 2019 Oct 14]. Available from: http://www.jsog.or.jp/modules/en/index.php?content_id=1.
   Google Scholar
• Thalidomide Welfare Center. [Internet]. Chiyoda-ku (TYO): Ishizue Foundation in Japan, [ cited 2019 Oct 14]. Available from: http://www008.upp.so-net.ne.jp/ishizue/index.html.
   Google Scholar
• Fact Sheet – pr THALOMID authorization for sale in Canada. [Internet]. Ottawa (ON): health Canada. Drug and health products; 2015 Apr 24 [cited 2019 Oct 14]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/fact-sheets/fact-sheet-thalomid-authorization-sale-canada.html.
   Google Scholar
• Controlled Drugs and Substances Act (S.C. 1996, c. 19). Ottawa (ON): health Canada. Consolidated Regulations; 2019 Sep 19 [cited 2019 Oct 14]. Available from: https://laws-lois.justice.gc.ca/eng/acts/c-38.8/.
   Google Scholar
• The Canadian Tragedy. [Internet]. Montreal (QB): Thalidomide Victims Association of Canada, [ cited 2019 Oct 14]. Available from: https://thalidomide.ca/en/.
   Google Scholar
• Consumer Packaging and Labelling Regulations (C.R.C., c. 417). Ottawa (ON): Health Canada. Consolidated regulations; 2019 Jun 17 [cited 2019 Oct 14]. Available from: https://laws.justice.gc.ca/eng/regulations/C.R.C.,_c._417/index.html.
   Google Scholar
• Canadian Thalidomide Survivors Support Program. [Internet]. Waterloo (ON): canadian Thalidomide Survivors Program, [ cited 2019 Oct 14]. Available from: https://tsspcanada.ca/.
   Google Scholar
• Central Drugs Standard Control Organization. [Internet]. New Delhi (DL): CDSCO. Drugs; [ cited 2019 Oct 14]. Available from: https://cdscoonline.gov.in/CDSCO/Drugs.
   Google Scholar
• National Leprosy Eradication Program. Disability Prevention and Medical Rehabilitation: guidelines for Primary, Secondary and Tertiary Level Care. [Internet]. India: central Leprosy Division; 2012. [cited 2021 Jun 14]. Available from: http://clinicalestablishments.gov.in/WriteReadData/516.pdf.
   Google Scholar
• Medicine Brands for Generic ‘Thalidomide.’ India: medicine India. Medicine Brands; [ cited 2019 Oct 14]. Available from: https://www.medicineindia.org/brands-for-generic/455/thalidomide.
   Google Scholar
• Leprosy/Hansen Disease: management of reactions and prevention of disabilities. Geneva: world Health Organization; 2020. [cited 2021 Jun 14]. Available from: https://www.who.int/publications/i/item/9789290227595.
   Google Scholar
• Comprehensive Newborn Screening (CNS) - Handbook for screening visible Birth Defects at all delivery points. India: national Health Mission; 2016. [cited 2019 Oct 14]. Available from: https://www.nhm.gov.in/images/pdf/programmes/RBSK/Resource_Documents/Birth_Defects_Handbook.pdf.
   Google Scholar
• The Medical Termination of Pregnancy Act, 1971. [Internet]. New Delhi (DL): Ministry of Health & Family Welfare. Acts, Rules and Standards for Health Sector; 2016 Nov 04 [cited 2019 Oct 14]. Available from: https://main.mohfw.gov.in/acts-rules-and-standards-health-sector/acts/mtp-act-1971.
   Google Scholar
• Thalidomide Celgene. [Internet]. Amsterdam (NL): European Medicines Agency. Human regulatory; 2008 Jan 04 [ cited 2019 Oct 14]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/thalidomide-celgene.
   Google Scholar
• VOLUME 9A of The Rules Governing Medicinal Products in the European Union – guidelines on Pharmacovigilance for Medicinal Products for Human Use. United Kingdom: European Medicines Agency; 2008.
   Google Scholar
• European Medicines Agency recommends the approval of thalidomide for the treatment of rare bone-marrow cancer. United Kingdom: european Medicines Agency; 2008.
   Google Scholar
• Bortezomib and thalidomide for the first‑line treatment of multiple myeloma. [Internet]. Nottinghamshire (UK): national Institute for Health and Care Excellence. NICE Guidance; 2011 Jul 27 [cited 2019 Oct 14]. Available from: https://www.nice.org.uk/guidance/ta228.
   Google Scholar
• European network of population-based registries for the epidemiological surveillance of congenital anomalies. [Internet]. European Union: EUROCAT, [ cited 2019 Oct 14]. Available from: https://eu-rd-platform.jrc.ec.europa.eu/eurocat.
   Google Scholar
• National Congenital Anomaly and Rare Disease Registration Service. [Internet]. London (UK): Government UK. Health and social care; 2015 Mar 27 [cited 2019 Oct 14]. Available from: https://www.gov.uk/guidance/the-national-congenital-anomaly-and-rare-disease-registration-service-ncardrs.
   Google Scholar
• Estudio Colaborativo Español de Malformaciones Congénitas [Spanish Collaborative Study of Congenital Malformations]. [Internet]. Madrid (ES): ECEMC; [ cited 2019 Oct 14]. Available from: http://www.fundacion1000.es/ecemc. Spanish.
   Google Scholar
• Les registres des malformations congénitales [Birth defect registers]. [Internet]. Paris (ILF): sante Publique France; 2019 May 20 [cited 2019 Oct 14]. Available from: https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-de-la-mere-et-de-l-enfant/anomalies-et-malformations-congenitales/articles/les-registres-des-malformations-congenitales. French.
   Google Scholar
• Thalidomide. [Internet]. Cambridgeshire (UK): the Thalidomide Trust; [ cited 2019 Oct 14]. Available from: https://www.thalidomidetrust.org/.
   Google Scholar
• Bundesverband Contergangeschädigter [Federal Association of Contergan Victims]. [Internet]. Munich (BY): thalidomide; [ cited 2019 Oct 14]. Available from: https://contergan.de/. German.
   Google Scholar
• The Thalidomide Society. [Internet]. Bromley (UK): Thalidomide Society; [ cited 2019 Oct 14]. Available from: https://www.thalidomidesociety.org/.
   Google Scholar
• Asociación de Víctimas de la Talidomida en España [Association of Victims of thalidomide in Spain]. [Internet]. Alcantarilla (MC): AVITE; [ cited 2019 Oct 14]. Available from: https://www.avite.org/. Spanish.
   Google Scholar
• German Criminal Code. [Internet]. Mohrenstraße (BE): federal Ministry of Justice and Consumer Protection. Laws on the Internet; 2019 Jun 19 [cited 2019 Oct 14]. Available from: http://www.gesetze-im-internet.de/englisch_stgb/englisch_stgb.html#StGB_000P218.
   Google Scholar
• Abortion Act 1967. [Internet]. London (UK): UK Legislation. UK Public general Acts; 2013 Apr 01 [cited 2019 Oct 14]. Available from: http://www.legislation.gov.uk/ukpga/1967/87/section/1.
   Google Scholar
• Ley Orgánica 2/2010, de 3 de marzo, de salud sexual y reproductiva y de la interrupción voluntaria del embarazo [Organic Law 2/2010, of March 3, 2010, on sexual and reproductive health and the voluntary interruption of pregnancy]. [Internet]. Madrid (ES): agencia Estatal Boletin Oficial Del Estado. Legislatión Consolidada; 2015 Sep 22 [cited 2019 Oct 14]. Available from: https://www.boe.es/buscar/act.php?id=BOE-A-2010-3514. Spanish.
   Google Scholar
• Abortion Legislation in Europe - Law No. 75-17 of January 1975. [Internet]. Washington (DC): library of Congress. Legislation. Legal Reports; 2018 Dec 30 [cited 2019 Oct 14]. Available from: https://www.loc.gov/law/help/abortion-legislation/europe.php#germany.
   Google Scholar
• World Health Organization. Global leprosy (Hansen disease) update, 2019: time to step-up prevention initiatives. Weekly Epidemiological Rec. 2020;95(36):417–440.
   Google Scholar
• Russel AM, Morrato RH, Lovett RM, et al. Quality of Reporting on the Evaluation of Risk Minimization Programs: a Systematic Review. Drug Saf. 2020;43(5):427–446. .
   PubMed Web of Science ®Google Scholar
• Castro MC, Massuda A, Almeida G, et al. Brazil’s unified health system: the first 30 years and prospects for the future. Lancet. 2019;394(10195):345–356. .
   PubMed Web of Science ®Google Scholar
• Diretrizes para vigilância, atenção e eliminação da Hanseníase como problema de saúde pública: manual técnico-operacional [Guidelines for surveillance, care, and elimination of leprosy as a public health problem: technical-operational manual]. Brasília (DF): ministério da Saúde; 2016. Portuguese.
   Google Scholar
• Sistema Eletrônico do Serviço de Informações ao Cidadão. Informações sobre aquisição, distribuição e casos de talidomida no Brasil [Electronic System of the Citizen Information Service. Information on thalidomide purchase, distribution, and cases in Brazil]. [Internet]. Brasília (DF): controladoria-Geral da União; [cited 2020 Nov 22]. Available from: https://esic.cgu.gov.br/sistema/site/index.aspx. Portuguese.
   Google Scholar
• Lis Y, Roberts MH, Kamble S, et al. Comparisons of Food and Drug Administration and European Medicines Agency Risk Management Implementation for Recent Pharmaceutical Approvals: report of the International Society for Pharmacoeconomics and Outcomes Research Risk Benefit Management Working Group. Value Health. 2012;15(8):1108–1112.
   PubMed Web of Science ®Google Scholar
• Guidance Document - Submission of Risk Management Plans and Follow-up Commitments. [Internet]. Ottawa (ON): health Canada. Drug and health products; 2015 Jun 26 [cited 2019 Oct 14]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/reports-publications/medeffect-canada/guidance-document-submission-risk-management-plans-follow-commitments.htm.
   Google Scholar
• Valproate and related substances [Internet]. Netherlands: european Medicines Agency; Medicines; 2018 Mar 21 [cited 2021 Jun 14]. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/valproate-related-substances-0.
   Google Scholar
• Mb M, DVA O. A talidomida no tratamento da reação leprótica [Thalidomide in the treatment of leprosy reaction]. Revista Brasileira de Leprologia. 1966; 37 (1–4): 41–49. Portuguese.
   Google Scholar
• Expert WHO Committee on Leprosy: eighth report. [Internet]. Geneva: world Health Organization; 2012 [cited 2019 Oct 14]. Available from: https://apps.who.int/iris/handle/10665/75151.
   Google Scholar
• Abreu DMX, Pinheiro PS, Queiroz BL, et al. Análise espacial da qualidade da Atenção Básica em Saúde no Brasil. Saúde Debate. 2018;42(spe1):67–80.
   Google Scholar
• Lima JG, Giovanella L, Fausto MCR, et al. Atributos essenciais da Atenção Primária à Saúde: resultados nacionais do PMAQ-AB. Saúde Debate. 2018;42(spe1):52–66.
   Google Scholar
• Leite SN, Manzini F, Alvares J, et al. Infraestrutura das farmácias da atenção básica no Sistema Único de Saúde: análise dos dados da PNAUM-Serviços [Infrastructure of primary care pharmacies in the Brazilian National Health System: analysis of PNAUM-Services data]. Rev Saúde Pública. 2017;51(Suppl2):13s. Portuguese.
   PubMedGoogle Scholar
• Pescarini JM, Strina A, Nery JS, et al. Socioeconomic risk markers of leprosy in high-burden countries: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2018;9(12):e0006622. .
   Google Scholar
• Nery JS, Ramond A, Pescarini JM, et al., Socioeconomic determinants of leprosy new case detection in the 100 Million Brazilian Cohort: a population-based linkage study. Lancet Glob Health. 2019;7(9): PE1226–E1236.
   PubMed Web of Science ®Google Scholar
• FCF L, APM C, Rfl D. Perfil epidemiológico da hanseníase na microrregião de Araçuaí e sua relação com ações de controle [Epidemiological profile of leprosy in the micro-region of Araçuaí and its relationship with control actions]. Esc. Anna Nery. 2011;15(1):62–67. Portuguese.
   Google Scholar
• Sousa GS, Silva RLF, Xavier MB. Hanseníase e Atenção Primária à Saúde: uma avaliação de estrutura do programa [Leprosy and Primary Health Care: an evaluation of program structure]. Saúde debate. 2017;41(112):230–242. Portuguese.
   Google Scholar
• Mf S, Lcm V, Pg F. Avaliação da implantação do Programa de Controle da Hanseníase em Camaragibe, Pernambuco [Evaluation of the implementation of the Leprosy Control Program in Camaragibe, Pernambuco State, Brazil]. Epidemiol. Serv. Saúde. 2017;26(4):817–834. Portuguese.
   PubMedGoogle Scholar
• Mendes A, Carnut L, Guerra LDS. Reflexões acerca do financiamento federal da Atenção Básica no Sistema Único de Saúde [Reflections on the federal financing of Primary Care in the Brazilian Unified Health System]. Saúde Debate. Portuguese. 2018;42(spe1):224–243.
   Google Scholar